Nucleus Network Acquires Hammersmith Medicines Research to Create Global Early-Phase Clinical Trial Network
核心洞察
Nucleus Network has acquired Hammersmith Medicines Research (搜索) (HMR), establishing the only early-phase clinical research provider with dedicated facilities across Australia, the United States, and the United Kingdom.
The acquisition creates a fully integrated global platform that enables studies to commence in one regulatory environment and seamlessly transition to another, accelerating timelines and reducing operational risk.
The combined organization expands access to broader and more diverse volunteer and patient populations, supporting faster recruitment and more inclusive study designs critical for first-in-human and adaptive trial protocols.
Nucleus Network, a global leader in early phase clinical research, has announced the acquisition of Hammersmith Medicines Research (搜索) (HMR), one of the United Kingdom's most respected early phase clinical trial organisations. This strategic acquisition establishes Nucleus Network as the only early phase provider with dedicated facilities in Australia, the United States, and the United Kingdom.
The acquisition brings together two organisations with a shared mission of advancing medicine and improving lives, while honoring the legacy of Dr Malcolm Boyce, whose leadership established HMR as a centre of excellence in early phase research across the UK and Europe.
Creating a New Global Standard
The acquisition positions Nucleus Network to set a new global benchmark in early-phase clinical trial delivery. Sponsors now benefit from a fully integrated model that combines global reach with deep local expertise. The organization's globally leading and multi-jurisdictional business development team will work in close partnership with sponsors to guide trials to geographic locations that best align with their strategic priorities.
"We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR's legacy," said Teena Pisarev, Chief Executive Officer of Nucleus Network. "This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered."
Enhanced Operational Capabilities
The expanded geographic footprint provides access to broader and more diverse volunteer and patient populations, supporting faster recruitment and more inclusive study designs that are critical for first-in-human and adaptive trial protocols. Studies can commence in one regulatory environment and seamlessly transition to another, enabled by harmonised processes and consistently high-quality standards, accelerating timelines and reducing operational risk.
HMR's decades of scientific and operational excellence complement Nucleus Network's advanced infrastructure and digital capabilities, bringing added precision to study execution and data quality while driving robust outcomes across all sites. Sponsors will experience more streamlined engagement through unified systems, shared best practices, and coordinated project delivery, simplifying the complexities of early-phase trial execution.
Continued Operations and Partnerships
Nucleus Network will continue to operate its clinical sites in Brisbane, Melbourne, and Sydney (from approximately 2026), Australia; Minneapolis, Minnesota; and London, England, ensuring continuity for ongoing studies and trusted relationships. The organization will also continue to partner with CROs around the world, offering flexible services that complement existing partnerships and extend reach across geographies.
"This acquisition expands what's possible for our sponsors," Pisarev added. "It deepens our scientific capabilities, strengthens our operational reach, and reinforces our commitment to delivering life-changing therapies to patients around the world."
Established Track Record
With over 20 years of experience and more than 1,500 first-in-human studies conducted, Nucleus Network is recognized for its scientific excellence, operational integrity, and commitment to innovation. The acquisition further strengthens the organization's position as the most experienced global provider dedicated to early-phase clinical research.